[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
[PDF][PDF] Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …
[HTML][HTML] Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …
began when the first sequence was published, and this forms the basis for …
[HTML][HTML] Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
…, D Dong, W Dejnirattisai, T Rostron, P Supasa… - Nature …, 2020 - nature.com
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
[PDF][PDF] Antibody evasion by the P. 1 strain of SARS-CoV-2
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …
[HTML][HTML] Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a …
…, W Dejnirattisai, X Liu, J Mongkolsapaya, P Supasa… - The Lancet, 2022 - thelancet.com
Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has
been widely used in a two-dose schedule. We assessed whether a third dose of the …
been widely used in a two-dose schedule. We assessed whether a third dose of the …
[HTML][HTML] Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
W Dejnirattisai, P Supasa, W Wongwiwat… - Nature …, 2016 - nature.com
Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease.
The recent explosive outbreak of ZIKV in South America has led to widespread concern, with …
The recent explosive outbreak of ZIKV in South America has led to widespread concern, with …
Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum
W Dejnirattisai, RH Shaw, P Supasa, C Liu, ASV Stuart… - The Lancet, 2022 - thelancet.com
According to WHO, SARS-CoV-2 is estimated to have caused 265 million infections and
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being
deployed at scale, aiming to generate responses against the virus spike. The scale of the …
deployed at scale, aiming to generate responses against the virus spike. The scale of the …